External price referencing (EPR) is applied more and more frequently worldwide by payers to control pharmaceutical prices. Together with the parallel trade of pharmaceuticals, EPR may result in lower pharmaceutical prices in higher-income countries and higher prices in lower-income countries, which implies that pharmaceutical expenditure grows more rapidly in the latter than in the former group. Our objective was to assess this hypothesis. We used hierarchical linear models on country-level panel data to show that-after controlling for compounding factors such as GDP, the proportion of the old-age population or life expectancy-the annual growth rate of pharmaceutical expenditure was 2.1% points larger in the lower-than in the higher-income members of the European Union between 2000 and 2008. This difference in trends became non-significant (0.6% points) after the onset of the global economic crisis. There was no significant difference between lower-and higher-income countries in the growth rate of non-pharmaceutical health expenditure in either period. Our results indirectly support the presence of price convergence of pharmaceuticals among European countries, and EPR and parallel trade may provide a reasonable explanation to the observed trend difference of pharmaceutical expenditure in the two groups of countries between 2000 and 2008. This higher growth rate of pharmaceutical expenditure put extra burden on public health care budgets in lower-income countries and resulted in disproportionately more cost-containment measures compared to higher-income countries after 2008. It remains to be seen whether the disappearance of the difference in trend growth rates due to special health policy interventions in countries with economic difficulties is temporary or permanent.
Introduction
In the European Union lower-income member states tend to spend less on health care both in absolute terms and as a percentage of GDP than their higher-income counterparts. However, as the price of medicines is less different across European countries compared to the costs of non-pharmaceutical health care services and the salary of health care professionals, lower-income countries spend more on pharmaceuticals as a proportion of total health care spending or as a proportion of GDP than higher-income ones (Kal o et al. 2012b , see also Table 1 later). The potentially differing trends of pharmaceutical expenditure according to income are much less studied, although it may be interesting from the policy perspective of external price referencing (EPR) and the parallel trade of pharmaceuticals.
External Price Referencing (EPR), or international reference pricing, involves the selection of a basket of countries to compare pharmaceutical prices and create a reference price for the country in question (Espin et al. 2011) . The purpose of EPR, among others, may be to negotiate or set prices within a country (Kanavos et al. 2010) .
It is applied more and more frequently both worldwide and in Europe, by payers who are aiming to control pharmaceutical prices (Carone et al. 2012) , and it seems to be an effective tool to reduce pharmaceutical prices (Galizzi et al. 2011; Leopold et al. 2012) . Regular price revision, referencing lower-income countries and mandate of the lowest price in the basket of reference countries are potentially important drivers of price reduction over time (Kal o et al. 2015) . Countries may also benefit from lower pharmaceutical prices if they delay the pricing decisions of new pharmaceuticals until many other European countries have already concluded on the price.
In the European Union, parallel trade of pharmaceuticals-when some products are legally imported from another country without the authorization of the manufacturer (Bouvy and Vogler 2013 )-has similar, although indirect effects. In the lack of EPR and parallel trade, manufacturers may have more incentives to adjust their prices to local purchasing power (this strategy is often called differential pricing), resulting in the increase of available funds for and global return on investment of pharmaceutical innovation, whilst ensuring lower prices and as a consequence, better access to medicines in lower-income countries (Danzon and Towse 2003; Kal o et al. 2013) . However, in the presence of EPR and parallel trade pharmaceutical companies try to implement narrow international price corridor for their most important medicines in order to minimize price erosion due to EPR and profit loss due to parallel trade (Ridley 2005) . Manufacturers also set a global launch sequence by introducing their new products in countries with traditionally high pharmaceutical prices, and reference these prices in other lowprice countries (Creativ-Ceuticals 2014; Leopold et al. 2014) .
As a testable consequence at the aggregate (country-) level, both EPR and parallel trade may result in lower pharmaceutical prices in higher-income countries and higher prices in lower-income countries, unless each higher-income country removes those countries from their reference basket that do not have comparable GDP per capita (Bouvy and Vogler 2013) . In theory, this implies two potential consequences in lower-income countries: (1) access to new pharmaceuticals becomes more limited for patients (Ridley 2005) ; and (2) the pharmaceutical expenditure grows more rapidly compared to higher-income countries. As limited patient access may have a negative impact on the popularity of policymakers, they tend to approve an increase in pharmaceutical spending, especially before parliamentary elections (Inotai et al. 2014) . This may further increase the rate of pharmaceutical expenditure in lower-income countries. In the above theoretical framework, Boehler (2013) simulated pharmaceutical price changes in Europe due to EPR, and concluded that EPR results in a narrow price corridor for new pharmaceuticals; there is a race to the bottom by countries to obtain the European floor price; and the European price erosion of new pharmaceuticals in the early period is faster than in later years.
Unfortunately the time-order relationship between EPR, parallel trade and increased pharmaceutical expenditure in lower-income countries is difficult to establish at an aggregate level, as e.g. the continuously strengthened application of EPR in Europe has to be considered in its continuum instead of a single intervention point. As current research methodologies and limited availability of data on net pharmaceutical prices across Europe prevented us from exploring the causal relationship between EPR, parallel trade and pharmaceutical expenditure, our research considered addressing their implications only indirectly. If pharmaceutical expenditure did not grow faster in lower-compared to higher-income countries, the implication of EPR and parallel trade on the European price corridor of new pharmaceuticals cannot be as important as presented in several papers (Ridley 2005; Kal o et al. 2013; Creativ-Ceuticals 2014) . On the other hand, the presence of a well-measured difference in growth rates of pharmaceutical expenditure yields indirect support to these phenomena. Therefore, our objective in this study was to assess the hypothesis (2) above, i.e. whether the growth rate of pharmaceutical expenditure is truly greater in lower-income than in higher-income European countries. We used hierarchical linear models to control for compounding factors such as GDP, proportion of the old age population and life expectancy at birth. We investigated the periods before and after the onset of the global economic crisis separately.
In addition, we estimated the income elasticity of pharmaceutical expenditure and compared it to the income elasticity of health care expenditure in general, obtained in this paper or given elsewhere in
Key Messages
• External price referencing and parallel trade result in lower pharmaceutical prices in higher-income countries and higher prices in lower-income countries, which implies that pharmaceutical expenditure grows more rapidly in the latter than in the former group.
• Using hierarchical linear models on country-level panel data, we show that-after controlling for compounding factorsthe annual growth rate of pharmaceutical expenditure was 2.1% points larger in the lower-than in the higher-income European countries between 2000 and 2008.
• This trend difference became non-significant after the onset of the global economic crisis, most probably due to disproportionately more pharmaceutical cost-containment measures in lower-income countries compared to higher-income ones.
the literature. It is reasonable to analyse pharmaceutical expenditure separately from other health expenditures since there is a remarkable cross-country variation both in its value and in its ratio to total health care expenditure in Europe (Lambrelli and O'Donnell 2009; OECD 2011) . Our paper also contributes to the scant literature of modelling pharmaceutical expenditure in a cross-country panel data setting (e.g. Clemente et al. 2008) . We selected variables that may influence health care expenditure in general and pharmaceutical expenditure in particular. According to Ke et al. (2011) , health care expenditure is affected by income, demand side (demographic and epidemiological) factors, technological progress and the characteristics of the health system. These variables are also determinants of pharmaceutical expenditure (Clemente et al. 2008; Lambrelli and O'Donnell 2009) . In our study, we measured income with GDP per capita, demographic factors with the proportion of the population above the age of 65 years, and we proxied technological progress with life expectancy at birth (c.f. Dreger and Reimers 2005) . The main dependent variable was the logarithm of pharmaceutical expenditure per capita but to compare our results with other studies, we also used the logarithm of nonpharmaceutical health expenditure per capita as the dependent variable in alternative equations.
Materials and methods

Data
As for monetary variables, euro was chosen as a common measure; national currency values (for Czech Republic, Denmark, Hungary, Poland, Sweden and the United Kingdom) appearing in the databases above were converted to euro on the given annual exchange rate available from public sources (ECB 2014). We chose to measure expenditure items in a common currency instead of the national currency or purchasing power adjusted currency because the prices of pharmaceuticals in different countries are compared in euro at the time of introduction.
The data sources did not cover all country-years, resulting in the presence of missing data. Missing data points within the period (altogether 16 out of 273 country-year points) were omitted from the analysis.
Methods
Association between potential explanatory variables and pharmaceutical expenditure as the outcome was assessed by performing descriptive statistical analysis. A series of linear regression models were fitted on each of the country-level explanatory variables and the outcome for the year with the most recent and complete recordings. Goodness of fit was evaluated by calculating correlation coefficients and by visual inspection of each fitted univariate model. The variables included in the exploratory analyses were GDP per capita (in euro), the proportion of the population above the age of 65 years (in per cent) and life expectancy at birth (in years).
To distinguish between higher-and lower-income countries within the European Union, a given country was considered higherincome if its GDP per capita exceeded mean GDP per capita in 2000 of the entire group of countries. Similarly, if the given country's GDP per capita did not exceed the mean GDP per capita in 2000, the country was taken into account in the lower-income group. This group consists of all new EU member states included in the analysis as well as Spain, Portugal and Greece (altogether nine countries), while the higher-income group includes the other 12 countries. As part of the preliminary analysis, we also examined graphically how the growth of pharmaceutical expenditure between 2000 and 2012 differed in the higher-vs. lower-income group. The two groups are well separated by income. Italy, the poorest member of the higher-income group, had 35% larger GDP per capita in 2000 than Spain, the richest member of the lower-income group. Meanwhile, nine members of the higher-income group were within the 35% range of Italy and three members of the lower-income group were within the same range of Spain. The two groups were stable between 2000 and 2012: although there was some reordering of countries within the groups, it remained true in the whole period that each country in the lower-income group had smaller GDP per capita than any country in the higher-income group.
For a more detailed analysis, we used hierarchical linear models (also known as random effects or mixed models) to describe the trends of pharmaceutical (and also of non-pharmaceutical) health spending levels in the higher-and lower-income group of countries, whilst controlling for the effect of multiple control variables and allowing country-specific random intercepts and random slopes (see e.g. Gelman and Hill 2007) . More precisely, our main specification was:
where i denotes country and t denotes year. ) is the logarithm of pharmaceutical expenditure per capita or of non-pharmaceutical health expenditure per capita, which are modelled with the time trend and with the vector of explanatory variables (X it ). The latter contains the logarithm of GDP per capita, the proportion of the population above 65 years and life expectancy at birth. As given in Equation (3), the time trend depends on whether the country is a higher-or lower-income country (denoted by L i , the dummy variable for being in the lower-income group), on whether the year is before or after the onset of the global economic crisis (denoted by the Pre t and Post t dummies, respectively) and on the interaction of these two variables. Hence in Equation (3) the parameters d Pre and d Post measure the growth in the higher-income group pre-and post-crisis, respectively, while the main parameters of interest are d LPre and d LPost , which show the difference in growth rates between the lowerand higher-income group before and after the onset of the crisis, respectively. The effects of the control variables are measured by the parameter vector b. The latter can be interpreted as an elasticity if both the dependent and the explanatory variable are given on the logarithmic scale.
To model the hierarchical (i.e. panel) structure of the data, the first-level intercept a i and time trend s it are allowed to vary by country (i.e. we allow country-specific random intercepts denoted by v i and random slopes denoted by w i in Equations (2)- (3)). Furthermore, we have the idiosyncratic error term e it in Equation (1). The three error terms v i ; w i ; e it ð Þare jointly normally distributed with variances r 2 v , r 2 w and r 2 e , respectively. The country-specific error terms are potentially correlated (their correlation coefficient is denoted by k) but they are assumed to be independent of e it .
We also fitted other models. In one specification, to examine the potential sensitivity of the results to the classification of countries into two groups, we measured economic development on a continuous scale and allowed the time trend to depend explicitly on initial (year 2000) logarithmic GDP per capita. More precisely, we estimated Equation (3') instead of (3): In another specification, we only allowed country-specific intercepts but not country-specific time trends, while in yet another model we allowed the idiosyncratic error term to follow an autoregressive process as in Baltagi and Wu (1999) . Finally, we also estimated a simplified version of model (1) Data analysis was carried out by using the R statistical software, its lme4 package (Bates et al. 2014 ) and the Stata statistical software.
Results and discussion Table 1 shows descriptive statistics of the dependent and explanatory variables in the higher-and lower-income European countries between 2000 and 2012. Both pharmaceutical and nonpharmaceutical health expenditure per capita were much lower in the lower-income group than in the higher-income group but there was a substantial variation (with the highest expenditure values in the lower-income group well exceeding the lowest expenditure values in the higher-income group). On average, the ratio of pharmaceutical to total health expenditure was 25% in the lower-income and 14% in the higher-income group, but again, the variations were large. Among the explanatory variables, the biggest difference between the two groups is observed in GDP per capita but life expectancy at birth was also markedly larger in higher-income countries than in lower-income ones. Figure 1 shows the time trends of pharmaceutical expenditure in the higher-and lower-income countries, suggesting smaller initial expenditure but a larger growth rate of expenditure in the lowerincome than in the higher-income group between 2000 and 2008. The difference in trends disappeared after the onset of the economic crisis: both groups of countries experienced stagnating (or even slightly decreasing) pharmaceutical expenditure in nominal terms between 2009 and 2012.
Based on descriptive statistical methods, there is an associative relationship between pharmaceutical expenditure and the three explanatory variables examined in this paper (Figure 2) . We obtained the following correlation coefficients with the logarithm of pharmaceutical expenditure in 2008: 0.757 (logarithm of GDP per capita), 0.157 (the proportion of the population above the age of 65) and 0.806 (life expectancy at birth). The bottom right panel of Figure 2 also shows that pharmaceutical expenditure is positively correlated with non-pharmaceutical health expenditure, although the relationship is far from deterministic (the correlation coefficient was 0.844 in 2008). Hence our strategy to examine the pharmaceutical expenditure separately from the rest of health expenditure-that is analysed in more detail in the literature-is justified. Hierarchical linear models make it possible to examine the growth rates of pharmaceutical expenditure in the two groups of countries after controlling for the other explanatory variables. The first column of Table 2 displays the parameter estimates of model (1)-(3) using the logarithm of pharmaceutical expenditure as the dependent variable. After controlling for other compounding factors, the annual growth rate of pharmaceutical expenditure was higher by 2.1% points (with 95% confidence interval [0.4, 3.7] ) in the lower-income than in the higher-income group of countries between 2000 and 2008. However, this statistically significant and substantial trend difference disappeared after 2008. The results of model (1)-(3') in the second column of Table 2 show that an e.g. 10% larger initial GDP per capita was associated with a 0.14% point lower annual growth rate of pharmaceutical expenditure between 2000 and 2008 (with 95% confidence interval [À0.25, À0.02]). Again, the trend difference by GDP per capita disappeared after 2008. Similar results (not shown here) were obtained when not the GDP per capita itself but the estimated potential GDP per capita (which intends to capture the pure economic performance of the countries in the absence of demand-side fluctuations) was used in the analysis.
The two other models used for robustness check and not reported in Table 2 (i.e. the random effects model without random slopes and the random effects model with autoregressive error terms) gave similar results: the trend difference was about 2.4% points before the onset of the crisis and not significant after that.
Meanwhile, even after controlling for other factors, the growth rate of pharmaceutical expenditure was much higher before 2008 than after it, so the flattened expenditure curves in Figure 1 cannot be fully explained by the changes in GDP per capita during the crisis. The GDP-adjusted trend growth rate was around 3.6% on average, 2.7% in the higher-income and 4.7% in the lower-income countries until 2008. After 2008 the average growth rate was not significantly different from zero (À0.8%) at the 5% level, and there was no significant trend difference between the higher-and lower-income countries.
We also fitted models without separating the two sub-periods (they are not reported in Table 2 ). In this case no statistically significant trend difference was observed between the pharmaceutical expenditure of the higher-and lower-income countries.
The country-specific intercepts of the hierarchical linear model (Equation (2) in model (1)- (3)) give information about the relative level of pharmaceutical expenditure of countries in 2008 after controlling for GDP per capita, the proportion of old-age population and life expectancy. According to Table 3, Greece was characterized by the largest intercept, i.e. the largest expenditure compared to countries with similar income and other explanatory variables (c.f. Lambrelli and O'Donnell 2011 , who analysed failed attempts to control pharmaceutical expenditure in Greece). the country-specific time trends before and after the onset of the economic crisis (calculated from Equation (3)). After controlling for the other explanatory variables, the model estimates a remarkably high (i.e. higher than 5%) pre-crisis trend growth rate of pharmaceutical expenditure for Estonia, Greece, Hungary, Ireland and the Slovak Republic (Greece having the largest slope). The vast majority of these countries belong to the lower-income group. Country-specific trend growth rates were generally negative or close to zero after 2008, with two exceptions (Greece and Ireland, both having trend growth rates above 2% even in this period). Figure 3 gives a picture about the country-specific hypothetical time trends and about the aggregate time trends in higher-versus lower-income countries of pharmaceutical expenditure by assuming that the explanatory variables (GDP per capita, the proportion of the population above the age of 65 and life expectancy at birth) were fixed at the given country's average level. These lines differ from those in Figure 1 because the effect of the explanatory variables was controlled for.
For comparison, the third and fourth columns of Table 2 provide estimates from models, in which the dependent variable is the logarithm of non-pharmaceutical health expenditure. In this case there is no statistically significant difference between the time trends of the higher-and lower-income countries in either period (although there is some difference in 2000-2008 if income is measured with GDP per capita on a continuous scale). Hence the difference of time trends observed above between the two groups is a feature of pharmaceutical expenditure not shared by health expenditure in general.
It is also interesting to compare the coefficients of the logarithm of GDP per capita (i.e. the income elasticities) in various models. Table 2 shows that a 1% increase of GDP per capita increases nonpharmaceutical health expenditure by around 0.90%. This is roughly in line with other estimates in the literature, which generally yield elasticities slightly lower than one (e.g. the elasticity of 0.87 in Baltagi and Moscone 2010). The income elasticity of pharmaceutical expenditure is slightly less (around 0.6) but note that in this model the effect of GDP is partially captured by a change in trends.
Theory predicts that external price referencing and parallel trade reduce prices of new pharmaceuticals in higher-income countries, and increase drug prices in lower-income ones, hence the growth rate of pharmaceutical expenditure will be higher in the latter compared to the former group. In this paper, we fitted various hierarchical linear models on country-level panel data to show that-even after controlling for compounding factors-this trend difference of growth rates was significant in the European Union between 2000 and 2008 but disappeared after the onset of the global economic crisis. Throughout the analysis, we measured expenditure items in a common currency (euro) because pharmaceuticals can be regarded as tradeable goods hence their prices can be compared in a common currency-at least at the time of their introduction in a new country. Therefore, for the purpose of the specific examination of pharmaceutical expenditure as opposed to health expenditure in general, the use of purchasing-power-parity-adjusted series (such as e.g. in Clemente et al. 2008) or series in national currency is not justified.
Our results support the presence of a narrowing price corridor and the convergence of pharmaceutical price differentials among European countries. Alternative explanations such as volume growth differences or composition effects are unlikely to explain the 2% point annual difference between the expenditure growths of the two groups in the 2000-2008 period. Although aggregate pharmaceutical consumption by volume is difficult to measure and reliable data sources are rare, sporadic evidence suggests that differences in volume growth cannot be so large. When comparing the volume of non-hospital pharmaceutical consumption between high-income and upper-middle income countries, Hoebert et al. (2011) found only a 2% point growth difference between 2002 and 2008. Hence, we expect a similarly small volume growth difference within the European Union in the given period. It is also possible but unlikely that a composition effect pushed up aggregate expenditure substantially more in the lower-income than in the higher-income European countries because empirical studies suggest an effect in the opposite direction, i.e. that new medicines tend to be introduced earlier in the higher-income than in the lowerincome European countries (Danzon et al. 2005) . Hence, we can conclude that price convergence lies in most part behind the observed expenditure trend differences, for which EPR and parallel trade provide the most plausible explanations (see also Glynn 2009; Leopold et al. 2012 ).
Higher growth rate of pharmaceutical expenditure put extra burden on health care budgets in lower-income countries and resulted in disproportionately more pharmaceutical costcontainment measures compared to higher-income countries after the onset of the global economic crisis (Vogler et al. 2011) . Examples include Greece, Portugal, Spain, Ireland, Hungary and the Baltic countries (Vandoros and Stargardt 2013; Garuoliene et al. 2011; Rü ü tel and Pudersell 2011; Behmane and Innus 2011; Kal o et al. 2012a; Leopold et al. 2014) . As a consequence the difference in trend growth rates disappeared after 2008. It remains to be seen whether this change due to cost-containment measures in countries with economic difficulties is temporary or permanent. If the EPR hypothesis is correct then the trend difference may return as soon as European economies achieve their normal growth path again.
Finally, it should be noted that there may be competing models for the trend difference of pharmaceutical expenditure in the two groups of countries. For instance, Lago-Penas et al. (2013) separated the long-and short-term effects of GDP on total health expenditure by including the potential GDP and the output gap (i.e. the trend and the cycle components of the GDP) as separate explanatory variables. However, pharmaceutical prices and pharmaceutical consumption should depend much less on the cyclical stance of the economy than other components of health expenditure such as the wage of health care employees, so a separate treatment of the potential GDP and output gap (which might partially explain the differing trends in the two groups) is much less justified for pharmaceutical expenditure than for total health expenditure. Moreover, we did not (2) and (3)) on pharmaceutical expenditure per capita (first column in Table 2 ). Table 2 ) when the explanatory variables are fixed at each country's average level. Logarithmic scale is used. Solid lines indicate higher-income, dashed lines lower-income countries.
The graph on the right shows group-wise means (of higher-vs. lower-income countries).
observe different trend growth rates of non-pharmaceutical health expenditure in the two groups of countries even between 2000 and 2008, which suggests a pharmaceutical-specific explanation for the trend difference-and this again points towards the EPR and parallel trend hypothesis.
Conclusion
Our study is among the first analyses to prove the higher growth rate of pharmaceutical expenditure in lower-income countries, a potential consequence of narrowing European price corridor of pharmaceuticals. As causal relationship between EPR, parallel trade and higher growth rate of pharmaceutical expenditure in lower-vs. higher-income countries could not be established, and we could not control country-specific pharmaceutical expenditure for changes in volume or prescription patterns, the generalizability of our conclusions is limited. In the future, the examination of product-level data of pharmaceutical consumption from different countries with panel data methods-as was done e.g. in Timur et al. (2011) without focusing on EPR and by Leopold et al. (2012) with descriptive and regression methods-may yield further evidence on the narrowing of the price corridor.
